Pfizer concludes Rs 110 cr deal with Piramal Enterprises

Published On 2016-09-27 10:45 GMT   |   Update On 2016-09-27 10:45 GMT

New Delhi : Drug maker Pfizer said it has completed the process of transferring four products to Mumbai-based Piramal Enterprises after getting necessary regulatory approvals.


"Post completion of requisite formalities and receipt of necessary regulatory approvals for the transaction, the company has concluded the transaction. Accordingly, the aforementioned products stand transferred to Piramal Enterprises," Pfizer said in a regulatory filing.


In May this year, Ajay Piramal-led Piramal Enterprises had entered into an agreement to acquire four brands from Pfizer for a consideration of Rs 110 crore.


The acquisition includes brands Ferradol, Neko, Sloan's and Waterbury's compound. The agreement also includes the trademark rights for Ferradol and Waterbury's Compound in Bangladesh and Sri Lanka.


Pfizer shares today ended at Rs 1,930.40 apiece on the BSE, down 1.66 per cent from previous close.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News